Page last updated: 2024-12-06

leminoprazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Leminoprazole is a proton pump inhibitor (PPI) that is used to treat gastroesophageal reflux disease (GERD) and other conditions associated with excess stomach acid. It works by blocking the production of gastric acid, which reduces the amount of acid in the stomach. Leminoprazole is a racemic mixture of two enantiomers, levorotatory and dextrorotatory. The levorotatory enantiomer is more potent than the dextrorotatory enantiomer. Leminoprazole is a highly effective drug for the treatment of GERD and other conditions associated with excess stomach acid. It is well-tolerated by most patients. Leminoprazole is synthesized in a multi-step process that involves the use of several different chemical reagents. The synthesis is complex and requires specialized equipment and expertise. Leminoprazole is studied to understand its mechanism of action and to develop new and improved treatments for GERD and other conditions associated with excess stomach acid. Leminoprazole is an important drug because it provides effective relief from the symptoms of GERD and other conditions associated with excess stomach acid. It is also studied for its potential to treat other diseases, such as cancer and Alzheimer's disease.'

Cross-References

ID SourceID
PubMed CID65881
CHEMBL ID2105102
SCHEMBL ID143739
MeSH IDM0237262

Synonyms (34)

Synonym
nc-1300-o-3
leminoprazole
leminon
104340-86-5
D05906
leminoprazole (inn)
2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline
leminoprazole [inn]
59h7g93y1t ,
(+-)-2-((o-(isobutylmethylamino)benzyl)sulfinyl)benzimidazole
unii-59h7g93y1t
nc1300o3
CHEMBL2105102
nc-1300o3
SCHEMBL143739
leminoprazole [jan]
benzenamine, 2-((1h-benzimidazol-2-ylsulfinyl)methyl)-n-methyl-n-(2-methylpropyl)-
2-(2-(n-isobutyl-n-methylamino)benzylsulfinyl)benzimidazole
(+/-)-2-((o-(isobutylmethylamino)benzyl)sulfinyl)benzimidazole
unii-5661mt8xqs
unii-s25l650735
5661MT8XQS ,
177541-00-3
benzenamine, 2-((1h-benzimidazol-2-ylsulfinyl)methyl)-n-methyl-n-(2-methylpropyl)-, (+)-
benzenamine, 2-((1h-benzimidazol-2-ylsulfinyl)methyl)-n-methyl-n-(2-methylpropyl)-, (-)-
leminoprazole, (-)-
S25L650735 ,
177541-01-4
leminoprazole, (+)-
benzenamine, 2-[(1h-benzimidazol-2-ylsulfinyl)methyl]-n-methyl-n-(2-methylpropyl)-;benzenamine, 2-[(1h-benzimidazol-2-ylsulfinyl)methyl]-n-methyl-n-(2-methylpropyl)-
2-(((1h-benzo[d]imidazol-2-yl)sulfinyl)methyl)-n-isobutyl-n-methylaniline
2-[(1h-benzimidazole-2-sulfinyl)methyl]-n-methyl-n-(2-methylpropyl)aniline
DTXSID50869422
AKOS040748734

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pretreatment with leminoprazole for 4 hr significantly prevented the reduction in cell viability caused by 50 microM indomethacin, although omeprazole was not effective."( The cytoprotective effect of leminoprazole on indomethacin-induced damage to rabbit gastric mucosal cells.
Okabe, S; Takahashi, S, 1996
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's14 (93.33)18.2507
2000's1 (6.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.38 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]